This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Dexcom patent declared invalid by UPC under 'whole content approach'

By Inbar Preiss ( December 11, 2024, 17:09 GMT | Insight) -- Healthcare firm Abbott notched a victory against Dexcom whose patent was revoked by the Unified Patent Court Paris Local Division. Judges found the patent lacks an inventive step and introduced new subject matter beyond the scope of the original application. Abbott's glucose monitoring system was accused of infringement, but the company successfully argued that Dexcom's patent amendments were unfit. The court applied a "whole-content approach" to assess when a patentee adds features beyond the original scope of its application.A Dexcom patent has been revoked across 18 EU countries by the Unified Patent Court in a win for Abbott, whose "FreeStyle Libre 3" continuous glucose monitor and related features were accused of infringement....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections